New narcolepsy treatments are being tested in the clinic, and recently, some of them have made promising strides. How far ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) shares rose 3.5% following the announcement of encouraging Phase 3 trial results for its investigational narcolepsy treatment, oveporexton. The Japanese ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts ...

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...

Narcolepsy with cataplexy, now known as type 1 narcolepsy, is a chronic neurological disorder that affects a person’s sleep-wake cycle and involves muscle weakness. The condition can cause a ...

NLS Pharmaceutics Unveils Promising Narcolepsy Treatment November 18, 2024 — 08:59 am EST Written by TipRanks Auto-Generated Newsdesk for TipRanks -> ...

The Breakthrough Therapy designation for AXS-12 for the treatment of cataplexy in narcolepsy was supported by the positive results from the Phase 2 CONCERT study, a randomized, double-blind ...

NLS Pharmaceutics Unveils Promising Narcolepsy Treatment TipRanks Nov. 18, 2024, 07:59 AM ...